| Literature DB >> 28293478 |
Shelli R Kesler1, Marjorie Adams2, Melissa Packer2, Vikram Rao1, Ashley M Henneghan3, Douglas W Blayney4, Oxana Palesh2.
Abstract
INTRODUCTION: Several previous studies have demonstrated that cancer chemotherapy is associated with brain injury and cognitive dysfunction. However, evidence suggests that cancer pathogenesis alone may play a role, even in non-CNS cancers.Entities:
Keywords: MRI; brain; cancer; cognition; connectome; fMRI; neuroimaging
Mesh:
Year: 2017 PMID: 28293478 PMCID: PMC5346525 DOI: 10.1002/brb3.643
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Demographic and medical variables
| Breast cancer, | Healthy controls |
|
| |
|---|---|---|---|---|
| Age | 49.8 (9.3) | 49.7 (10.0) | 0.057 | .95 |
| Age range | 29–66 | 26–64 | ||
| Education (years) | 17.0 | 17.5 | −1.083 | .28 |
| Minority status | 33% | 20% | 2.46 | .117 |
| Postmenopausal | 45% | 40% | 0.328 | .567 |
| Disease stage at diagnosis (0, I, II, III) | 6%, 35%, 47%, 11% | |||
| Days since diagnosis | 38 (26) | |||
| Estrogen receptor positive | 89% | |||
| Progesterone receptor positive | 75% | |||
| Estrogen/progesterone receptor positive | 75% | |||
| HER2 positive | 24% | |||
| BRCA (BRCA1 positive, BRCA2 positive) | 9%, 9% |
HER2, human epidermal growth factor receptor 2; BRCA, breast cancer susceptibility.
Cognitive and self‐report measures
| Breast cancer ( | Healthy controls ( |
|
|
| |
|---|---|---|---|---|---|
| RAVLT total recall | 52.5 (8.6) | 56.1 (7.6) | 7.64 | .01 | .02 |
| RAVLT interference | 5.82 (1.8) | 6.76 (1.8) | 8.21 | .01 | .02 |
| RAVLT delayed recall | 10.9 (2.7) | 11.6 (2.2) | 3.07 | .08 | .12 |
| CTMT 1 | 50.7 (7.3) | 55.5 (9.7) | 9.16 | .003 | .02 |
| CTMT 2 | 52.7 (10.6) | 54.2 (10.4) | 0.45 | .50 | .56 |
| CTMT 3 | 50.1 (8.2) | 50.1 (10.1) | 0.01 | .91 | .91 |
| CTMT 4 | 54.8 (10.1) | 56.5 (10.1) | 0.46 | .50 | .56 |
| CTMT 5 | 50.6 (8.8) | 54.0 (9.5) | 4.35 | .04 | .07 |
| COWA | 42.5 (13.0) | 49.5 (12.8) | 7.44 | .01 | .02 |
| BRIEF GEC | 51.3 (9.2) | 45.3 (9.8) | 0.74 | .39 | |
| PRMQ | 36.7 (8.8) | 32.8 (8.2) | 0.89 | .35 | |
| CAD | 52.0 (9.8) | 43.7 (9.6) | 22.8 | <.0001 |
RAVLT, Rey Auditory Verbal Learning Test; CTMT, Comprehensive Trail Making Test; COWA, Controlled Oral Word Association; BRIEF GEC, Behavioral Rating Inventory of Executive Function Global Executive Composite; PRMQ, Prospective and Retrospective Memory Questionnaire; CAD, clinical assessment of depression; FDR, false discovery rate.
Higher scores on the BRIEF, PRMQ, CAD = elevated symptoms. Higher scores on all other measures = better performance.
Brain network metrics
| Breast cancer ( | Healthy controls ( |
|
| |
|---|---|---|---|---|
| Functional connectome global clustering coefficient | 0.54 (0.03) | 0.53 (0.03) | 1.78 | .19 |
| Structural connectome global clustering coefficient | 0.69 (0.005) | 0.70 (0.005) | 0.26 | .61 |
| Structural connectome size | 8,521 (48) | 8,531 (49) | 0.01 | .92 |
| Functional network dynamics (Hurst exponent) | 0.19 (0.10) | 0.22 (0.11) | 1,271 | .046 |
Figure 1Local differences in brain network metrics. Compared to controls, patients with breast cancer showed altered functional clustering (FC, cyan) in right inferior parietal lobe, right middle inferior orbital frontal gyrus, and right medial superior frontal gyrus (p < .05, uncorrected). The breast cancer group showed altered structural clustering (SC, blue) in right inferior and middle frontal gyri, bilateral postcentral gyri, right precuneus, and left inferior temporal gyrus (p < .05, uncorrected). Functional dynamics as measured by Hurst exponent (FD, magenta) was lower in patients with breast cancer compared to controls in right inferior orbital gyrus, left middle occipital gyrus, right parietal lobule, right cuneus, right superior temporal gyrus, and right inferior temporal gyrus (p < .05, uncorrected)
Figure 2Correlations between brain network metrics. The breast cancer group demonstrated a significant negative correlation between structural and functional clustering as well as a significant positive correlation between functional clustering and Hurst exponent. Values are shown as r(p). SC, structural connectome clustering; FC, functional connectome clustering; FD, functional dynamics (Hurst exponent). *The group difference between these correlations was significant (p = .03)
Figure 3Relationship of structural and functional principal component and cognitive function in patients with breast cancer. Greater cognitive dysfunction was associated with greater overlap between structural and functional connectome clustering (r = 0.34, p = .005). MHD, Mahalanobis distance; higher MHD = greater cognitive dysfunction